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Galectins (formerly known as “S-type lectins”) are a subfamily of soluble proteins
that typically bind β-galactoside carbohydrates with high specificity. They are present
in many forms of life, from nematodes and fungi to animals, where they perform
a wide range of functions. Particularly in humans, different types of galectins have
been described differing not only in their tissue expression but also in their cellular
location, oligomerization, fold architecture and carbohydrate-binding affinity. This distinct
yet sometimes overlapping distributions and physicochemical attributes make them
responsible for a wide variety of both intra- and extracellular functions, including
tremendous importance in immunity and disease. In this review, we aim to provide
a general description of galectins most important structural features, with a special
focus on the molecular determinants of their carbohydrate-recognition ability. For that
purpose, we structurally compare the human galectins, in light of recent mutagenesis
studies and novel X-ray structures. We also offer a detailed description on how to
use the solvent structure surrounding the protein as a tool to get better predictions
of galectin-carbohydrate complexes, with a potential application to the rational design
of glycomimetic inhibitory compounds. Finally, using Gal-1 and Gal-3 as paramount
examples, we review a series of recent advances in the development of engineered
galectins and galectin inhibitors, aiming to dissect the structure-activity relationship
through the description of their interaction at the molecular level.
Keywords: galectin, structure, carbohydrate, water sites, docking, drug-design, glycomimetic
GALECTINS IN CELLULAR BIOLOGY
Deciphering the complex structure of the sweet pattern elegantly disposed over different cell
surfaces requires a wide variety of biomolecules specifically designed to interact with each particular
moiety. Understanding the structure, dynamics, and recognition mechanism of the proteins
responsible for this role is therefore of fundamental relevance to gain a deeper understanding of the
underlying biological processes involved and develop potential therapeutic interventions. Galectins
are one of the main groups of carbohydrate recognition proteins, and in humans, they are involved
in a variety of physiological processes, many of which are directly linkedwith immunity and disease.
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Galectins arose lately as novel actors in the modulation
of physio-pathological processes. They have been implicated
in many biological activities, ranging from functional early
developmental processes, vascularization programs, cell
migration, and regulation of immune system cells to either pro-
or anti-inflammatory resolutions (Liu and Rabinovich, 2010;
Di Lella et al., 2011; Thiemann and Baum, 2016). Galectins are
deeply involved in pathogen recognition and killing, and in
facilitating entry of microbial pathogens and parasites into the
host (Vasta, 2009; Yang et al., 2011; Baum et al., 2014; Lujan
et al., 2018). During infection, they are the subtle intermediators
that decipher glycan-containing information about the host
immune cells and microbial structures, and therefore modulate
a diversity of signaling events that lead to cellular proliferation,
survival, chemotaxis, trafficking, cytokine secretion, and
cell-cell communication.
Extracellularly, most galectins act as soluble cell surface
pattern recognition receptors, by these means regulating
cell-cell communication (Arthur et al., 2015b). Their lectin
activity, specifically directed toward β-galactoside moieties,
is either coupled with a dimerization equilibrium, in tandem
multi carbohydrate binding domain structure, or other
oligomerization strategies, that prompt the formation of very
complex supramolecular structures, often described as lattices
(Sacchettini et al., 2001). In summary, the mechanism through
which galectin extracellular functions are accomplished relies
both on their carbohydrate-binding specificity, as well as on
their lattice formation capabilities which are tightly related to
galectin structure.
GALECTIN STRUCTURE
As described originally by Hirabayashi and Kasai (1993),
galectins can be classified according to their domain organization
in three groups: (i) the prototype galectins, which display a single
Carbohydrate Recognition Domain (CRD) per polypeptide
and usually form dimers, represented in humans by Gal-
1,−2,−7,−10,−13, and−14; (ii) tandem repeat-type galectins,
displaying two CRDs in tandem, represented by Gal-4,−8,−9,
and−12; and finally the (iii) chimera-type galectins, where the
CRD is fused to another non-lectin domain, represented by Gal-
3 (Liu and Rabinovich, 2010; Di Lella et al., 2011; Thiemann and
Baum, 2016). On the other hand, phylogenetic analysis based on
sequence and intron/exon positions revealed two monophyletic
groups referred to as F3 and F4 CRD types (Houzelstein
et al., 2004). Interestingly, all tandem repeat-type galectins are
composed of one CRD of each type.
Galectin’s CRD (Figure 1) can be described as an about
∼130–140 residue domain which folds as a two antiparallel β-
sheet sandwich that adopts a closing hand shape. The backhand
is formed by strands F1 to FX (which form the F-sheet),
while the palm consists of strands S1 to SY (the S-sheet). In
all galectins, the carbohydrate-binding site (CBS) is located
in a groove in the S-sheet side of the sandwich, and the β-
galactoside recognition core motif is mediated by sheets S4, S5,
and S6.
Comparative sequence and structural analysis, shows some
interesting trends of galectin structural divergence. The first
thing to notice is that despite having a low (∼30% average)
sequence identity, the CRD fold structure is highly conserved:
the maximum backbone Root Mean Square Deviation (RMSD)
between all human galectins is below 2.2 Å, with the main
differences observed in specific loop regions (Figure 2A). The
structure also seems to follow sequence evolution, with all
galectins from the same CRD type (F3/F4) clustering together
in the RMSD tree (Figure 2B), and close sequence pairs (i.e.,
Gal-1/Gal-2 or Gal-10/Gal-13) displaying very similar structures.
A particular interesting observation concerns tandem type
galectins, since they always combine two domains which are both
sequence and structural divergent. Finally, it is worth mentioning
that the C-terminal domain of Gal-12 seems to be the most
divergent galectin domain, sharing <20% sequence identity to
any other galectin, and whose structure is currently unknown.
LINKING OLIGOMERIC STRUCTURE TO
FUNCTION
Going back to the oligomeric structure, it is important to note
that prototype galectins form dimers of two CRDs back to back
and that both states seem to exist in a dynamical equilibrium,
which has been shown, at least in Gal-1, to affect ligand binding
kinetics and affinity (Di Lella et al., 2010; Nesmelova et al.,
2010; Romero et al., 2016). A clear example of the oligomeric
state affecting immune function is that only dimeric Gal-1,
but not its permanent monomeric mutant form, is able to
induce phosphatidylserine exposure and enhance phagocytic
recognition of leukocytes (Dias-Baruffi et al., 2003).
Tandem repeat-type galectins, as their name evidence, display
two CRDs covalently connected in tandem by a hinge region,
thus no dynamical equilibrium is possible. This constitutive
bivalency of tandem repeat-type galectins has been proposed as
an explanation of why and how they induce cell signaling at lower
concentrations than those of proto-type galectins. Supporting
this idea, many independent studies have shown dissimilar
potencies of different galectins upon triggering particular cellular
responses. For example, when looking at T lymphocytes and
neutrophils signaling, tandem repeat-type Gal-4,−8, and−9 are
more potent than the chimera-type Gal-3, the latter being more
potent than the proto-type Gal-1 (Sturm et al., 2004; Levy et al.,
2006; Stowell et al., 2007). Supporting key role of (supra) domain
structure, the orientation, rotational flexibility, and spacing of
the CRDs in tandem repeat-type galectins has been shown to
modulate its lattice forming capabilities (Rabinovich et al., 2007).
The above described structural mechanisms of lattice formation,
impacts directly in galectin-based protein engineering strategies
for therapeutic purposes, as exemplified by a covalently linked
form of the Gal-1 dimer (i.e., an engineered tandem repeat type
Gal-1), which was found to be a potent pro-apoptotic agent on
mouse thymocytes as well as mature T lymphocytes at lower
concentrations compared to the wild-type (Bättig et al., 2004).
Concerning Gal-3, its unique type of possible oligomeric states
deserves particular attention. Gal-3 is monovalent in the absence
Frontiers in Chemistry | www.frontiersin.org 2 December 2019 | Volume 7 | Article 823
Modenutti et al. The Structural Biology of Galectin-Ligand Recognition
FIGURE 1 | Structure of a Galectin. (A) Gal-1 dimer. (B) Detail of the Gal-1 monomer differentiating the “S-sheet” (strands S1–S6) in yellow, and the “F-sheet” (strands
F1–F5) in red. All cysteine side chains drawn as Balls and sticks.
FIGURE 2 | (A) Structural alignment of all available human Galectin CRDs X-ray structures. Blue-colored regions correspond to the lowest RMSD values and red to
the highest values. Gal-1 structure used as reference. Each loop is named after the two β-strands it connects. (B) Backbone RMSD-based tree (left) and amino acid
sequence identity tree (right) of the X-ray structures.
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of ligands, but can oligomerize through its N-terminal non-lectin
domain upon ligand recognition by its lectin C-terminal galectin
CRD (Ahmad et al., 2004). This oligomerization, and further
lattice formation process, leads to cross-linking of glycoprotein
receptors on the cell surface, which is an essential event for the
majority of Gal-3 extracellular functions, such as cell adhesion
and T cell activation (Yang et al., 2008).
While the macromolecular structure of organized clustered
assemblies could be evidenced by electron microscopy of
homogeneous and heterogeneous lectin-carbohydrate cross-
linked complexes in other lectins (Dam et al., 2017), only blobs
in EMs of precipitates of Gal-3 with bivalent pentasaccharides
has been observed (Ahmad et al., 2004). The functional
activity of a pro- or anti-inflammatory galectin could be
explained in terms of the quaternary structure -the organization
of these supramolecular assemblies. While Gal-1, displaying
anti-inflammatory features, remains a dimer in cross-linked
complexes with a bivalent oligosaccharide, Gal-3, a pro-
inflammatory lectin, is predominantly a monomer in solution,
converting into a pentamer in the presence of a precipitating
multivalent carbohydrate. Additionally, and due to its dimeric
equilibrium, Gal-1 can form one-dimensional and homogeneous
lattices, while Gal-3 forms heterogeneous cross-linked complexes
with multivalent carbohydrates (Ahmad et al., 2004).
GALECTIN CARBOHYDRATE
RECOGNITION
Galectins’ CBS is formed by the residues within the groove
comprising the S-sheet. From a general point of view, binding
of carbohydrates involves at least two major interactions:
hydrophilic, through an extensive complementary hydrogen-
bond network, and hydrophobic, through CH-π interactions
between the sugar and aromatic amino acid sidechains in
the CRD. An in-depth binding affinity analysis of a large
oligosaccharide library covering a diverse set of mammals, fungi,
nematode and Porifera galectins has been carried by Hirabayashi
et al. (2002).
In galectins, the minimum binding determinant, usually a
Lactose or N-acetyl-lactosamine disaccharide, binds to the far
side of the CBS (strands S4–S6), although there are several
reported complex structures with larger saccharides. Using one
of the largest available as reference -the Gal-9N hexasaccharide
complex (PDB id: 2zhm)- in order to facilitate the analysis the
whole CBS can be divided into six different “monosaccharide
binding subsites,” which we will refer to as sites Y, Z, A, B, C, and
D. Comparative analysis of the protein residues related to each
subsite in several human galectins (Figure 3A) show that while
there are highly conserved topological positions, others seem to
allow the presence of many types of amino acids. Most conserved
residues give shape to subsites C and D (Figure 3B). Particularly,
“subsite C” deserves a detailed structural description, since it
is the one that comes into most intimate contact with the
β-galactoside moiety, hence could be the most implicated in
galectins’ characteristic specificity. It essentially consists of a
pocket-shaped region formed by three conserved positions along
the S4 strand, His at 4-S4, Asn at 6-S4, and Arg at 8-S4, plus
a conserved Trp at position 2-S6 (Figure 3C). The three polar
residues of S4 are implicated in accommodating the axial C4-OH
-the distinctive feature of galactoside epimers- through multiple
hydrogen-bonding interactions, while the Trp interacts with the
opposite face of the sugar through its CH-π cloud.
Computational calculation of each individual site-
monosaccharide interaction energy by the Generalized Born
(GB) method also showed some interesting trends (Guardia
et al., 2011). As it can be observed in Figure 3D, sites that
contribute most to the binding affinity are subsites C and D.
Particularly, subsite C showed a high contribution of Van Der
Waals interactions to the total energy, that can be explained by
the pocket-like shape of the site. On the other hand, subsite D
showed mainly electrostatic contributions, due to the presence of
a conserved negatively-charged Asp at position 5-S6, and a less
well-conserved positively-charged residue at position 7-S6. Most
of these characteristics are in agreement with a broader analysis
made by our group for a larger and more diverse set of lectins,
which show that even if some lectins are able to accommodate
large oligosaccharides, most lectins typically recognize a core of
one or two monosaccharide units, and usually no more than 2–3
OH groups per monosaccharide are in contact with the protein,
with a total average of 4-OH groups being responsible for ligand
recognition (Modenutti et al., 2015).
Despite being commonly considered as galectins for
exhibiting the characteristic jelly roll-like CRD, from a ligand-
binding perspective there are special cases to underscore that
arguably deserve to be included in this classification. One is
the C-terminal domain of the human hematopoietic stem cell
precursor, commonly called GRP for “galectin-related protein,”
which has no apparent ability to bind carbohydrates (Zhou et al.,
2008). Figure 3C shows that these could be due to the fact it lacks
4 out of the 6 most conserved residues, the previously described
His, Asn, Arg, and Trp of subsite C. A second special case is Gal-
13 (also known as Placenta Protein 13), which has proven to be
unable to bind lactose by both crystallographic and biochemical
analysis. However, the Gal-13 R53H-H57R double mutant (PDB
id: 6a62) was proven to recover the lactose-binding capabilities
(Su et al., 2018a), thus suggesting that it possibly changed its
binding capacity due to a few recent evolutionary steps. The
structural explanation behind this clever work of re-engineering
lays in the fact that in Gal-13 position 53 corresponds to the key
His and position 57 to the Arg of subsite C, which as mentioned
above are necessary for hydrogen bonding the axial C4-OH.
Finally, the most controversial case is possibly that of Gal-10,
which has shown little affinity toward β-galactosides, yet its
structure has been co-crystallized with mannose (PDB id: 1qkq)
(Swaminathan et al., 1999). A close inspection of the structure
immediately reveals that the mannose ring is distorted from
its classical low-energy chair conformation and that it is not
completely buried into the CBS, thus making it difficult to think
of mannose as its endogenous ligand.
The difference in Gal-10 behavior seems to concern domain
organization, as recently demonstrated by Su et al., who showed
that Gal-10 dimerizes in a different way to other prototype
lectins, that is, through the S-sheet face of the CRD; in this
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FIGURE 3 | Amino Acid composition of human galectins’ CBS based on a topological analysis (Gal-12C excluded). (A) Probability graph for each topological position.
Each residue is colored by its physicochemical properties. The protein topology naming corresponds to the piece of secondary structure under study, preceded by a
number which indicates the relative position of each particular residue in that piece of secondary structure (e.g., “5-S2” corresponds to the position no. “5” of the “S2”
β-strand). (B) Tridimensional representation of the Gal-9N, with the main residues of the CBS surface, highlighted as yellow (most conserved) or purple (least
conserved). Hexasaccharide molecule is depicted with red lines and its monosaccharide units named with letters Z-Y-A-B-C-D. (C) Residue comparison along S4-S6
β-strands. (D) Individual contribution per monosaccharide to the total Binding Energy, calculated with the General Born method (Guardia et al., 2011). “Reprinted
(adapted) with permission from Guardia et al. (2011). Copyright (2011) American Chemical Society”.
novel dimerization mode, the F2S3 loop residue Glu 33 from
one monomer partially occludes the CBS of the other and
vice versa, hence preventing the binding of lactose (Su et al.,
2018b). However, when this Glu is mutated to Ala, dimerization
equilibria is altered and now the monomeric Gal-10 E33A can
bind lactose. This idea is strongly supported by the recently
solved crystal structure of the Gal-10 E33A mutant in complex
with lactose (PDB id: 6a1t), and by hemagglutination inhibition
experiments. Also, the CBS involvement in Gal-10 dimerization
is further backed up by the mutation of the conserved C subsite
Trp to Ala; Gal-10 W72A mutant is indeed a monomer, hence
confirming the participation of Trp 72 in dimerization. Gal-10
W72A agglutination capabilities are enhanced with respect to
wild-type, as well as its ability of binding to lactose-modified
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FIGURE 4 | Solvent structure of several human galectins. (A) Apo X-rays superimposition showing highly ordered crystallographic water molecules in the CBS. Color
code is cyan for Gal-1 (1w6n-B), magenta for Gal-3 (3zsm-A), green for Gal-7 (4gal-A), orange for Gal-8N (3apb-B), and yellow for Gal-9C (3nv1-A). (B) Detail of Gal-1
(1w6o-A) in complex with lactose, showing the main polar residues and the Hydrogen bond network (dotted lines) established with the ligand. (C) Superimposition of
A and B, showing that a clear displacement of water molecules is needed for binding to proceed.
sepharose-6B beads in solid-phase assays (Su et al., 2019). This
raises the question as to whether the conserved C subsite Trp
regulates lactose binding negatively, and more shallow binding
sites such as that of Gal-10 W72A could rather increase affinity.
THE ROLE OF WATER IN GALECTIN
CARBOHYDRATE RECOGNITION
Water molecules play an important role in protein structure
and function. During the ligand-binding process, the water
molecules from the corresponding binding site must be displaced
to make room from the incoming ligand, which is also
partially solvated. Several works have shown that this solvent
reorganization process has an important contribution to the
binding free energy (Lazaridis, 1998; Abel et al., 2008). Most
importantly, the hydrophilic nature of both the carbohydrate
ligands and the galectins CBS makes this contribution a key
element in the recognition process and the resulting affinity.
From a structural point of view, and as a result of the
specific interactions between the CBS surface and the water
solvent, water molecules tend to occupy specific positions and
orientations (i.e., they are highly ordered), resulting in a well-
defined solvent structure. This ordered solvent structure can be
revealed for example by the presence of crystallographic waters
(Figure 4A), or as will be described below, using Molecular
Dynamics simulations, yielding the so-called “Water Sites”
(WS). Previous analysis from our group for a large dataset of
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FIGURE 5 | Solvent structure determination by Molecular Dynamics of Gal-7 CBS (PDB id: 1bkz). Water molecules from many snapshots along the simulation
trajectory are superimposed and shown as small cyan dots (Hydrogens atoms omitted for clarity). (A) Water Sites 1–5 are depicted as transparent yellow circles. (B)
N-acetyl-lactosamine coordinates of “PDB id: 5gal” superimposed into the previous image, highlighting all the oxygen atoms that displace a Water Site.
lectin-carbohydrate complexes showed that up to 80% of all
observed ligand -OH groups that interact with their receptors
are, when the ligand is absent, occupied by a WS. On the
other hand, of all WS found in the CBS of lectins, about
40% tend to be replaced by ligand-OH groups (Modenutti
et al., 2015). Figure 4A shows how these WS are precisely
located and perfectly describe the binding mode of β-galactosides
in galectins.
Looking at the sugar ligand, it is evident as the name
“carbohydrate” suggests, that they can be structurally/chemically
described as “hydrated carbons,” and upon binding their -OH
groups perform the same interactions with the protein as those
performed by the WS (Figures 4B,C, 5B). In other words, the
WS structure mimics the ligand -OH framework that interacts
with the protein and therefore can be an excellent predictor for
recognition and affinity.
MOLECULAR SIMULATION METHODS AS
STRUCTURAL BIOLOGY TOOLS FOR
STUDYING GALECTINS AND
CARBOHYDRATES
Molecular simulation methods, mainly classical force field-
based Molecular Dynamics simulations and Molecular Docking,
have been extensively used to study carbohydrates, lectins, and
their complexes. In particular, explicit water simulations allow
a detailed description of the solvent structure in the Lectin
CBS in terms of WS (Gauto et al., 2009). A WS corresponds
to a definite region in the space adjacent to the protein
surface, where the probability of finding a water molecule is
significantly higher than that observed in the bulk solvent. It
has been proven that there is a correlation between the WS
and the crystallographic waters (Modenutti et al., 2015) and
can be structurally and thermodynamically characterized in the
context of the Inhomogeneous Fluid Solvation Theory (Lazaridis,
1998). Several methods are available for WS determination, like
WaterMap (Abel et al., 2008), WATsite (Hu and Lill, 2014), GIST
(Nguyen et al., 2012), and WATclust (López et al., 2015), to cite
a few.
In WATclust, for example, WS is detected through clustering
of explicit water molecules, through a graphic interface
implemented in the commonly spread Visual Molecular
Dynamics software (Humphrey et al., 1996). Briefly, to detect
WS, the program should be fed with a collection of trajectory
snapshots (∼500–1,000, which usually cover 5–20 ns) derived
from the corresponding simulation of the desired protein
embedded in a large explicit water box. The snapshots are
superimposed using a local RMSD-based structural alignment, in
which the residues selected for the alignment should reflect the
region of interest, usually the CBS. Subsequently, the number of
snapshots harboring a water oxygen atom in a previously defined
space region (with an arbitrary spherical volume of 1 Å3) are
determined, and those regions with a high population (>10–
50% of the total number of snapshots) are selected as candidate
WS (Figure 5A).
Once identified, for each candidate WS two important
parameters are computed, namely: (i) The “Water Finding
Probability” (WFP), defined as the probability of finding a
water molecule in the 1 Å3 volume and normalized with
respect to the probability of the bulk water; (ii) The “R90”,
which corresponds to the radius in which 90% of the water
molecules can be found. This parameter gives a notion of the
WS dispersion, and thus its translational entropy; candidate
water clusters whose WFP is below 2–5 are usually discarded,
and the remaining are considered the true WS. As will be
described below, the WS predictive capacity leads us to develop
a WS-biased docking methodology which significantly improves
the quality of structure predictions both in terms of accuracy
and specificity.
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WATER SITES AS PREDICTORS OF
GALECTIN-CARBOHYDRATE BINDING
Molecular Docking methods, such as the widely used Autodock
(Forli et al., 2016), aim to determine the structure of a protein-
ligand complex and the corresponding affinity (i.e., the Binding
free energy’), starting from the structure of the protein receptor
and the ligand separately. Therefore, they are commonly utilized
to determine the precise complex structure of a known binding
protein-ligand pair (usually referred as “pose prediction”), or
to predict the structure and affinity of a series of potential
ligands for a given receptor (referred to as “virtual screening”)
(Arcon et al., 2019a). Docking methods usually consist of a
conformational search algorithm coupled to an energy scoring
function that estimates the Binding Free Energy (Morris et al.,
1998). Scoring functions are usually developed and calibrated
for rigid hydrophobic drug-like compounds stored in deep
hydrophobic pockets of their respective receptors, hence, they
typically perform poorly when trying to dock polar ligands
such as carbohydrates that bind to lectins’ shallow and solvent-
exposed CBSs.
Based on our previous finding that WS tend to mimic
the carbohydrate -OH groups in the resulting lectin-sugar
complexes, we hypothesized this information could be used to
improve carbohydrate docking performance. The idea, which
we called the “Solvent-Site Bias Docking Method” (SSBDM)
was implemented in Autodock 4 (Arcon et al., 2019b), and it
basically adds a correction term to the Autodock energy scoring
function to bias the ligand oxygen atoms toward replacing the
WS coordinates, as described by Equation (1):








((x− xWS,i)2 + (y− yWS,i)2 + (z − zWS,i)2)
R90
(1)
FIGURE 6 | Docking calculations of N-acetyl-lactosamine disaccharide to Gal-1 structure (PDB id: 1y1u). Results are presented as “Population vs. Binding Energy,”
and a picture of the Best energy-ranked result for each docking method. (A) Conventional Autodock Docking Method. (B) Solvent-site Bias Docking Method
(SSBDM). The values next to the dots represent the ligand heavy atom RMSD between the predicted ligand pose and the reference X-ray pose. The red dot indicates
the location of the most accurate result.
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Here, 1G0 corresponds to the original Autodock 4 scoring
function Binding Energy, WFPi is the water-finding probability
of the “ith” WS. XWS, YWS, and ZWS are the corresponding WS
cartesian coordinates, and R90 is the WS dispersion factor.
This way, in the SSBDM each WS provides a favorable
interaction energy between the center of theWS position and any
oxygen atom of the ligand, with a magnitude that is proportional
to the “Ln(WFP)” and an amplitude related to the WS dispersion
“R90.” In other words, those poses of the carbohydrate that
maximize superposition of the -OH groups to where theWS with
highestWFPwere located are favored in terms of Binding Energy.
The SSBDM has proven to be an efficient structure predictor
for many protein-carbohydrate complexes, including some
galectins (Gauto et al., 2013). An example of the method increase
in performance is shown in Figure 6. Docking calculations
typically return a set of probable ligand poses, ranked by their
Binding Energy and sometimes reporting the pose “population”
(understood as the percentage of times that the corresponding
pose was found). Figure 6 shows a classic “Population vs. Binding
Energy” plot for 100 Docking runs of N-acetyl-lactosamine to
Gal-1, where each dot corresponds to a different ligand pose.
Highlighted in red is the “correct pose” (i.e., that with a 0.6 Å
heavy-atom RMSD with respect to the N-acetyl-lactosamine in
the reference complex, PDB id: 1y1u). Figure 6A shows that for
conventional docking the correct pose is indistinguishable from
other poses with similar values of energy and/or population.
Figure 6B, on the other hand, illustrates how the SSBDM
increases the predictive power of Docking, since it enriches the
correct pose both in terms of energy and population, making it
now easily distinguishable from false positives.
Currently, as of 2019, the SSBDMhas been officially integrated
into the AutoDock suite as an easy-to-use script, by the name of
“AutoDock Bias” (Arcon et al., 2019a).
Nevertheless, the pose prediction of larger saccharides (i.e.,
beyond the trisaccharide level) is still a challenging task and
requires additional patches. Common docking calculations often
decrease their success rate when dealing with large ligands
TABLE 1 | Docking results of carbohydrates of different sizes onto their respective




Gal-2 1HLC-B Lactose Disaccharide 6.1
Bovine Gal-1 1SLT-B N-acetyl-
lactosamine
Disaccharide 7.0
Gal-8N 3AP7-A Sialyllactose Trisaccharide 1.0
Gal-9C 3NV4-A Sialyllactose Trisaccharide 0.8
Gal-9N 2EAL-A Forssman antigen Trisaccharide 0.4












that have several active torsions, especially when these torsions
result in a large conformational space, as in the case of
short oligosaccharides. To address this problem, Nivedha et al.
successfully implemented an ad hoc potential function for
Autodock Vina scoring function, which energetically penalizes
those conformations that fall too far from the glycosidic dihedral
angles minima, significantly optimizing the performance for
large carbohydrates. This method is called “Vina-Carb”(Nivedha
et al., 2014, 2016), and as shown in Table 1, it was proven
successful for the prediction of many galectin-oligosaccharide
complexes. Noteworthy examples are the case of the sialyllactose
trisaccharide docking to both Gal-8N and Gal-9C receptor
structures. Even more strikingly, it was able to give an accurate
prediction of the N-acetyl-lactosemine hexasaccharide pose in
Gal-9N (RMSD 1.90 Å). Yet strangely, Vina Carb performed
poorly (RMSD > 3) for the two disaccharide complexes listed.
This could be indicating that for small saccharides the Carb
energy functions are still not enough for a guaranteed success,
and might support the idea that a combination of techniques -
torsional penalties and the incorporation of the solvent structure-
is probably the best strategy.
Molecular Docking methods enable the investigator to
access an atomistic-detailed comprehension of the protein-
carbohydrate interaction and thus provide a state of the art tool
for the rational design of glycomimetic binders. Furthermore,
it would be interesting to know the aftermath of applying such
methods to predictively discern binders from non-binders in
glycan-array experiments. Currently, an important line of work
in this direction is being developed in our lab.
GALECTINS AS THERAPEUTIC AGENTS
AND DRUG TARGETS
The identification of critical regions in galectin’s structure that
determine their biophysical properties and interactions with
the microenvironment can be exploited in the design of novel
proteins with particular features. Furthermore, understanding
their unique structural features is the key to overcoming
the difficulties in designing specific glycomimetic ligands for
therapeutic purposes. Two of the most studied galectins to date
in this respect are Gal-1 and Gal-3, being in the bullseye of the
scientific community as well as the pharmaceutical industry, they
both serve as examples of the paramount importance of galectins
and their ligands in immunology related Translational Medicine
(St-Pierre et al., 2012; Téllez-Sanz et al., 2013).
GALECTIN-1 AND
PROTEIN-ENGINEERING
The high levels of expression of Gal-1 in the thymus, lymph
nodes, as well as in immune cells such as T cells and activated
macrophages, suggested from the very beginning a key role in
immune response regulation. Early evidence for the potential of
Gal-1 therapeutic applications came from several experiments
with rodent models (Levi et al., 1983; Offner et al., 1990;
Santucci et al., 2003), as well as from evidence of low expression
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levels of Gal-1 and increased anti-Gal-1 antibodies in human
patients with diverse forms of arthritis (Harjacek et al., 2001;
Xibillé-Friedmann et al., 2013). In order to utilize Gal-1 as a
therapeutic agent, first difficulties to overcome were those related
to its varying functionality and efficiency due to its different
physicochemical states, namely the oxidized vs. reduced forms,
and monomer-dimer equilibrium (Blanchard et al., 2016).
A distinctive characteristic of some galectins is the
requirement of a reducing environment for carbohydrate-
binding activity. The rationale behind this property is based on
the presence of a variable number of cysteine residues. Gal-1
for example, contains 6 cysteines in its 135 residue monomer
(Figure 1B), and many studies have established a critical
interplay between Gal-1 ligand binding activity and cysteine
redox state (Stowell et al., 2009; Guardia et al., 2014; Arthur et al.,
2015a). This characteristic should not go unnoticed given the
sensitivity of Gal-1 to oxidative inactivation and its functional
role in inflammatory microenvironments, where there is a high
propensity toward oxidation. Sensitivity of Gal-1 to oxidation
was cleverly addressed by Nishi et. al., with the generation of a
cysteine-less Gal-1 mutant. This “perpetually reduced” mutant
showed enhanced stability over the wild-type, while retaining
its hemagglutination and inhibition of cell-growth capabilities
intact (Nishi et al., 2008). On the other hand, an “oxidized”
form of Gal-1 with a disulfide bond between Cys16-Cys88 has
been patented for nerve regeneration treatments (Horie et al.,
2005). This oxidized variant is to be further covalently bound to
soluble polymers such as polyethylene glycol, to enhance both
stability and solubility. A detailed analysis of the involvement
of every cysteine residue revealed a different correlation on
their importance for disulfide bond formation and further lectin
activity inactivation (Guardia et al., 2014).
Regarding the dimerization state, wild type Gal-1 and several
dimer-interface mutants with notably higher dimerization
constants were patented for inflammatory modulation
applications, in which the dimer were to be used to kill
FIGURE 7 | Scheme of Gal-3 most important cellular functions in tumoral environments (Green arrows mean activation and bordeaux lines mean inhibition).
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FIGURE 8 | Galectins in complex with carbohydrate-derived monovalent inhibitors. (A) Thiodigalactoside “TD139” superimposed complexes of Gal-3 (magenta, PDB
id: 5h9p) and Gal-7 (green, PDB id: 5h9q) (B) Taloside inhibitors superimposed complexes. Gal-1 and methyl 2-O-acetyl-3-O-toluoyl-beta-D-talopyranoside (cyan,
PDB id: 3T2T), Gal-3 and methyl 3-deoxy-2-O-toluoyl-3-N-toluoyl-beta-D-talopyranoside (magenta, PDB id: 3T1M).
activated neutrophils (anti-inflammatory effect), while the
monomeric stable mutants were to be used to block the
neutrophils apoptosis (pro-inflammatory effect) (Cummings
and Cho, 1999). These dimer-interface mutants include
single mutations (such as C2S or V5D), as well as a multisite
mutant called “N-Gal-1” (bearing C2S, L4Q, V5D, and A6S
mutations) (Cho and Cummings, 1996). In the opposite
direction, in an effort to increase the relatively low in vivo
potency of monomeric forms, a rational design of a series
of covalently-linked Gal-1 dimers have been engineered.
Following the pioneer “two-glycine covalent linker” (Bättig
et al., 2004), various linkers of different lengths and flexibilities
were explored, such as the 14 residue long random coil linker
of Gal-9 (Bi et al., 2008), the 34 residue long helix linker
from bacterial ribosomal L9 protein (Earl et al., 2011), and
a 33 residue long flexible linker of Gal-8 (Vértesy et al.,
2015). Each of these linker variants led to both increased
hemagglutination and increased T-cell apoptosis promotion.
The rationale behind the improved potency could presumably
be the formation of more stable supramolecular structures
(Baum, 2011).
Last but not least, Dimitroff et al. engineered a chimera
protein of murine Gal-1 and the Fc region of human
Immunoglobulin G1, which showed similar levels of activity as
the native Gal-1 but stronger stability. This peculiar protein
product showed pro-inflammatory toward activated leukocytes
of rheumatoid arthritis patients and bears a patent for the
treatment of immune disorders (Dimitroff et al., 2013). In
summary, it is clear that a deep understanding of structural and
physicochemical characteristics of Gal-1 in the context of its
biological function, has been a key issue for the development of
therapeutic approaches.
GALECTIN 3 AND DRUG-DESIGN
Several studies have demonstrated Gal-3 involvement in
tumorigenesis, malignant form transformation, and metastasis
(Radosavljevic et al., 2012). Gal-3 helps tumor cells them
to escape immune surveillance by blocking both the afferent
arm (T cell proliferation) and efferent arm (T cell attack)
of the immune system response. A summary of both Gal-
3 intratumoral and extracellular functions is schematized in
Figure 7. As a result, inhibition of Gal-3 is strongly considered
as a way of helping to restore the immune system’s ability to
fight cancer.
Most popular inhibitors of Gal-3 fall into one of three
categories: Firstly, the peptide-derived inhibitors, perhaps
headed by the sixteen amino acid long peptide “G3-C12,”
obtained from phage display (Zou et al., 2005); Secondly,
The carbohydrate-derived multivalent inhibitors, represented
mostly by the pectin derivatives, examples of which are
the citrus-pectin derived “GBC-590” and “GCS-100” (both
by Safescience, Inc.), or the galactomannan “GM-CT-01”
(DavanatTM) and galactoarabino-rhamnogalacturonan “GR-MD-
02” (both by Galectin Therapeutics, former Pro-Pharmaceuticals,
Inc.). Inhibitors from these two categories are already undergoing
phase II clinical trials, and have been extensively described by
Blanchard et al. (2014).
The third category and perhaps the most relevant to
describe in detail under the structural scope of this review is
comprised by the carbohydrate-derived monovalent inhibitors.
They originally consisted of either galactose, lactose or N-
acetyllactosamine scaffolds, in which their free -OH groups
were to be modified with diverse chemical substituents. This
fragment-based approach of drug design soon established the
so-called “thio-digalactoside” (TDG) scaffold” and its derivatives
as some of the most prominent small-molecule inhibitors of
Gal-3 (Cumpstey et al., 2005), given the extra resistance to
both chemical and enzymatic hydrolysis conferred by a sulfur
bond. Among these compounds, we can cite the C2-symmetric
“TD139” (by Galecto Biotech) or its asymmetrical derivative
“TAZTDG” by Hsieh et al. (2016).
Modifications of TDG scaffold as a strategy to increase
the binding affinity and, at the same time, improve specificity
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is supported under the premise that the different galectins
present variations in their protein sequences at subsites Z,
Y, A, and B. Taking as an example the case of TD139, this
antagonist has been co-crystallized with Gal-1 (PDB id: 4y24),
Gal-3 (PDB id: 5h9p) and Gal-7 (PDB id: 5h9q). Although
the ligand exhibits similar binding modes for Gal-1 and Gal-3,
a remarkably different conformation is observed in the Gal-7
complex (Figure 8A), involving a disfavourable rotation of one
of its 4-fluorophenyl substituents, prompted by the presence
of a His residue at position 3 of the S3 strand (near the
subsite B), in contrast to the less bulky Val occupying this
same position in Gal-1 or the Ala in Gal-3. This difference in
the structure offers a simple albeit elegant explanation to the
several orders of magnitude in their ITC-determined dissociation
constants (Gal-7 Kd = 38µM, Gal-3 Kd = 0.068µM)
(Chan et al., 2018).
Another promising carbohydrate scaffold that is able to
bind in the galectins subsite C is the taloside. Talose is the
C2 epimer of galactose, featuring an axial C2-OH group (as
opposed to the equatorial of galactose) (Collins et al., 2012).
This enables the incorporation of axial substituents at this
position which, depending on their shape, can interact with the
surface of strands S4 and S5, as well as with the S4–S5 loop.
This particular loop (as previously shown in Figure 2A) has
both variable amino acid composition and length across the
several lectins, and has been proven to have a wide flexibility as
evidenced by Molecular Dynamics simulations (Guardia et al.,
2011). Each particular loop structural difference and dynamical
behavior could be rationally exploited in favor of improving
ligand specificity. Examples that support this idea are shown in
Figure 8B, where it can be clearly shown that Gal-3 is able to
accommodate larger C2 substituents thanGal-1, due to its shorter
S4–S5 loop.
As a final remark, we would like to emphasize that, while
peptide and multivalent carbohydrate-derived inhibitors show
very promising results in experiments and clinical trials, their
weak spot lies in the fact that their structural mechanisms of
binding are unknown. On the contrary, this is the small-molecule
monovalent inhibitors strongest feature, since their development
involves a rational understanding of both the ligand and the
target physicochemical characteristics. An in depth description of
carbohydrate-derived monovalent inhibitors for Gal-3 has been
thoroughly reviewed by St-Pierre et al. (2012) and Téllez-Sanz
et al. (2013).
CONCLUSIONS
When looking at galectins overall fold, it is clear that
the conserved scaffold of the CRD allows for a subtle
shaping of each CBS, which are expected to result in
different affinities for different carbohydrate ligands, yielding
a possibly unique selectivity which combined with particular
domain architecture and environmental modulation (i.e., redox
state, level of expression) produces a potential variety of
biological responses. A comparative analysis on CBS amino acid
composition across several human galectins reveals conserved
positions that strongly correlate with having important roles
in binding, especially regarding the binding pocket of the
β-galactoside moiety. This pocket is formed by conserved
residues His, Asn, Arg and Trp, which apparently cannot
be freely mutated without producing serious consequences to
ligand affinity.
Water molecules play an important role in lectin-
carbohydrate recognition. The identification of Water Sites
allows for an accurate description of the solvent structure
surrounding the CBS, information which in turn can be craftily
taken advantage of by incorporating it to Docking schemes,
enhancing their predictive power. Carbohydrate dihedral angle
energy penalties might also be of great aid when dealing with
complex oligosaccharides. Molecular Docking for prediction
of protein-ligand complexes is becoming an essential tool in
structural biology.
All the above mentioned roles played by galectins in cell
communication, proliferation, and migration, plus their active
participation in immunological processes, make clear that
galectins are directly involved in many diseases, such as cancer
development and progression, HIV and microbial infections,
autoimmune disorders, allergies, cardiovascular diseases, and the
list continues. In this context, Gal-1 and Gal-3 have particularly
withdrawn the attention of the scientific and pharmaceutical
community, given their ubiquity and their direct relation to
disease. They have been subject not only of protein engineering
studies with therapeutic purposes, but also as extensive drug-
design protocols.
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